Tags

Type your tag names separated by a space and hit enter

[Spanish experience with insulin lispro].
An Med Interna. 1998 Jul; 15(7):384-90.AM

Abstract

Insulin lispro is an analog of human insulin created when the amino acids at positions 28 and 29 of the B-chain of insulin are reversed. The natural sequence in human insulin at these positions is proline at B28 and lysine at B29. At physiologic concentrations, insulin lispro exists in solution as a monomer. As such, it's rate of absorption from subcutaneous sites of injection is greater that of regular insulin. The pharmacokinetic and pharmacodynamic profiles of insulin lispro indicate that it is more rapid-acting, and therefore a more physiological mealtime insulin than regular insulin. In addition, it shows a shorter duration of activity, approximately up to 5 hours. Insulin lispro given 0 to 15 minutes before the meal translate into better glycemic control and less hypoglycemia risk in clinical studies either in type 1 or type 2 diabetes when compare with regular human insulin given 30-45 minutes before meals.

Authors+Show Affiliations

Reviriego Fernández J
Departamento de Investigación Clínica, Lilly, S.A. Madrid.

MeSH

AdultClinical Trials as TopicClinical Trials, Phase II as TopicClinical Trials, Phase III as TopicDiabetes Mellitus, Type 2FemaleHumansHypoglycemic AgentsInjections, SubcutaneousInsulinInsulin LisproInsulin, IsophaneMaleMiddle AgedMulticenter Studies as TopicTime Factors

Pub Type(s)

Comparative Study
English Abstract
Journal Article
Review

Language

spa

PubMed ID

9710993

Citation

Reviriego Fernández, J. "[Spanish Experience With Insulin Lispro]." Anales De Medicina Interna (Madrid, Spain : 1984), vol. 15, no. 7, 1998, pp. 384-90.
Reviriego Fernández J. [Spanish experience with insulin lispro]. An Med Interna. 1998;15(7):384-90.
Reviriego Fernández, J. (1998). [Spanish experience with insulin lispro]. Anales De Medicina Interna (Madrid, Spain : 1984), 15(7), 384-90.
Reviriego Fernández J. [Spanish Experience With Insulin Lispro]. An Med Interna. 1998;15(7):384-90. PubMed PMID: 9710993.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Spanish experience with insulin lispro]. A1 - Reviriego Fernández,J, PY - 1998/8/26/pubmed PY - 1998/8/26/medline PY - 1998/8/26/entrez SP - 384 EP - 90 JF - Anales de medicina interna (Madrid, Spain : 1984) JO - An Med Interna VL - 15 IS - 7 N2 - Insulin lispro is an analog of human insulin created when the amino acids at positions 28 and 29 of the B-chain of insulin are reversed. The natural sequence in human insulin at these positions is proline at B28 and lysine at B29. At physiologic concentrations, insulin lispro exists in solution as a monomer. As such, it's rate of absorption from subcutaneous sites of injection is greater that of regular insulin. The pharmacokinetic and pharmacodynamic profiles of insulin lispro indicate that it is more rapid-acting, and therefore a more physiological mealtime insulin than regular insulin. In addition, it shows a shorter duration of activity, approximately up to 5 hours. Insulin lispro given 0 to 15 minutes before the meal translate into better glycemic control and less hypoglycemia risk in clinical studies either in type 1 or type 2 diabetes when compare with regular human insulin given 30-45 minutes before meals. SN - 0212-7199 UR - https://www.unboundmedicine.com/medline/citation/9710993/[Spanish_experience_with_insulin_lispro]_ L2 - https://medlineplus.gov/diabetesmedicines.html DB - PRIME DP - Unbound Medicine ER -